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For patients with acute lymphoblastic leukemia (ALL) who relapse after allogeneic hematopoietic stem cell
transplantation (HSCT), treatment options are limited, and the clinical course and prognostic factors affecting
outcome have not been well characterized. We retrospectively analyzed outcomes of 123 adult patients with
ALL who relapsed after a ﬁrst HSCT performed at our center between 1993 and 2011. First-line salvage
included second HSCT (n ¼ 19), donor lymphocyte infusion with or without prior chemotherapy (n ¼ 11),
radiation therapy (n ¼ 6), cytoreductive chemotherapy (n ¼ 30), mild chemotherapy (n ¼ 27), or palliative
care (n ¼ 23), with median postrelapse overall survival (OS) of 10 months, 6.5 months, 3 months, 4 months,
4 months, and 1 month, respectively. Despite a complete remission rate of 38% after ﬁrst-line salvage in the
treated patients, the OS rate remained limited with 1- and 2- year OS rates of 17% (95% conﬁdence interval, 13
to 29) and 10% (95% conﬁdence interval, 6 to 20), respectively. On univariate analysis, adverse factors for OS
included active disease at the time of ﬁrst HSCT and short time to progression from ﬁrst HSCT (<6 months).
There was no difference in the 6-month survival postrelapse in patients with isolated extramedullary relapse
(44%) compared with combined extramedullary and bone marrow relapse (29%) or those with isolated bone
marrow relapse (34%) (P ¼ .8). Our data provide more insight into the disease behavior and treatment
outcomes of ALL at relapse after HSCT against which future trials may be compared.
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Treatment outcomes for adults with acute lymphoblastic
leukemia (ALL) have improved during the last few decades.
Measures such as optimized chemotherapy regimens,
modeled after pediatric regimens [1,2]; risk stratiﬁcation
withminimal residual diseasemonitoring [3,4], development
of novel agents [5,6], and improvements in supportive care
have led to improvement in survival rates. Results from
a number of trials, including the pivotal MRC/UKALL XII/
ECOGE2993 trial, have led tomore interest in the up front use
of allogeneic hematopoietic stem cell transplantation (HSCT)
for both standard-risk and high-risk ALL patients [7,8].
Patients with ALL who relapse after HSCT have a poor
prognosis. Some patients do respond to subsequent treat-
ment, and prognostic factors for these patients are not well
characterized. Few studies have evaluated management of
ALL relapse after HSCT. Spyridonidis et al. [9] reviewed the
registry data from the European Blood and Marrow Trans-
plantation (EBMT) group and demonstrated a median post-
relapse survival of only 5.5 months and an estimated 5-year
postrelapse survival of 8%  1%. Using a multivariate model,
the authors reported a prognostic model at the time of
relapse.
The nature of a retrospective registry study, however,
precludes a more in-depth look at speciﬁc patientdgments on page 1063.
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13.04.014medullary (EM) relapse. In addition, limited data are
available on factors such as discontinuation of immunosup-
pressive therapy (IST), as well as more details on salvage
therapy and its responses, and the impact of these factors on
the outcomes of the patients. Examinations of these issues
are warranted to guide postrelapse management decisions
and to explore novel therapeutic interventions. We per-
formed a single-center retrospective analysis on adults with
hematological relapse after ﬁrst HSCT for ALL in an attempt
to better characterize these issues.
METHODS
Patient Inclusion Criteria and Data Collection
This retrospective analysis included all adult ALL patients, age 18 years
or older, who had undergone ﬁrst HSCT at M.D. Anderson Cancer Center
between 1993 and 2011 and subsequently relapsed. Patients were treated on
transplantation protocols that were available during the different time
periods. Collected data included patient and disease characteristics at
diagnosis, disease status at time of ﬁrst HSCT, source of stem cells, allotype of
donor, conditioning regimens, graft-versus-host disease (GVHD) prophy-
laxis, incidence of acute and chronic GVHD after transplantation, duration of
posttransplantation remission, leukemia burden at relapse, details of
salvage therapy and outcome variables, including response, overall survival
(OS), and cause of death. Institutional review board approval was obtained
for this retrospective study.
Deﬁnitions
Cytogenetic abnormalities were classiﬁed based on previously pub-
lished reports [10]. Myeloablative and reduced-intensity conditioning
regimens were deﬁned according to the Center for International Blood and
Marrow Transplantation Research criteria [11]. Criteria for complete
response (CR) included normal cytogenetics, the absence of circulating
blasts, and less than 5% marrow blasts. The disease stage at transplantationTransplantation.
Table 1
Overall Characteristics of Relapsed Patients by Salvage Treatment Group
Characteristic Overall
(n ¼ 123)
HD
Chemotherapy
(n ¼ 30)
HSCT  Chemotherapy
(n ¼ 19)
DLI  Chemotherapy
(n ¼ 11)
Gentle
Chemotherapy
(n ¼ 27)
Radiation or IT
only (n ¼ 6)
Palliative
(n ¼ 23)
Median age, yr (range) 31 (18-70) 38 (21-64) 31 (19-51) 35 (23-53) 27 (18-70) 34 (22-42) 29 (18-68)
Response pretransplantation
Disease in remission 83 (67%) 25 (83%) 15 (79%) 5 (45%) 19 (70%) 3 (50%) 11 (48%)
Active disease 40 (33%) 5 (17%) 4 (21%) 6 (55%) 8 (30%) 3 (50%) 12 (52%)
Histology
B lineage 95 (77%) 23 (77%) 17 (89%) 8 (73%) 22 (81%) 3 (50%) 16 (70%)
T lineage 28 (23%) 7 (23%) 2 (11%) 3 (27%) 5 (19%) 3 (50%) 7 (30%)
Cytogenetic risk category*
High risk 46 (37%) 13 (43%) 9 (47%) 5 (45%) 10 (37%) 1 (17%) 7 (30%)
Others 53 (43%) 12 (40%) 9 (47%) 3 (27%) 12 (44%) 1 (0%) 12 (52%)
Unknown 24 (20%) 5 (17%) 0 (0%) 4 (36%) 5 (19%) 4 (67%) 4 (17%)
Site of relapse
Systemic relapse 99 (80%) 23 (77%) 17 (89%) 10 (91%) 23 (85%) 0 (0%) 19 (83%)
Isolated EMy 24 (20%) 7 (23%) 2 (11%) 1 (9%) 4 (15%) 6 (100%) 4 (17%)
Preparative regimen
Myeloablative 91 (74%) 24 (80%) 16 (84%) 8 (73%) 17 (63%) 4 (67%) 16 (70%)
RIC 32 (26%) 6 (20%) 3 (16%) 3 (27%) 10 (37%) 2 (33%) 7 (30%)
Allo type
Matched unrelated donor 45 (37%) 9 (30%) 4 (21%) 7 (64%) 9 (33%) 1 (17%) 12 (52%)
Matched related donor 65 (53%) 16 (53%) 14 (74%) 4 (36%) 15 (56%) 5 (83%) 7 (30%)
Mismatched related 6 (5%) 4 (13%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (9%)
Umbilical cord blood 7 (6%) 1 (3%) 1 (5%) 0 (0%) 3 (11%) 0 (0%) 2 (9%)
Time from HSCT to progression
6 mo 81 (66%) 15 (50%) 7 (37%) 7 (64%) 22 (81%) 4 (67%) 21 (91%)
6 mo 42 (34%) 15 (50%) 12 (63%) 4 (36%) 5 (19%) 2 (33%) 2 (9%)
PB blasts at relapse
10% 96 (78%) 24 (80%) 13 (68%) 10 (91%) 21 (78%) 6 (100%) 18 (78%)
10% 27 (22%) 6 (20%) 6 (32%) 1 (9%) 6 (22%) 0 (0%) 5 (22%)
EBMT scorez (n ¼ 83) (n ¼ 25) (n ¼ 15) (n ¼ 5) (n ¼ 19) (n ¼ 3) (n ¼ 11)
Score 0-1 43 (52%) 18 (72%) 10 (67%) 4 (80%) 7 (37%) 1 (33%) 2 (18%)
Score 2-3 40 (48%) 7 (28%) 5 (33%) 1 (20%) 12 (63%) 2 (67%) 9 (82%)
HD indicates high dose; IT, intrathecal; RIC, reduced-intensity conditioning; PB, peripheral blood.
Overall survival was calculated from the time of progression.
* Cytogenetic risk category based on National Comprehensive Cancer Network (NCCN) guidelines 2012 [10].
y Locations were CNS (n ¼ 16), lymph node (n ¼ 5), joints (n ¼ 2), testes (n ¼ 1), and others (n ¼ 5). Five patients had more than 1 site of extramedullary
relapse.
z Based on study by Spyridonidis et al. [9]. Applied to patients in study who underwent HSCT while in remission.
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best response occurring after day 30 after HSCT. Hematological relapse was
deﬁned by recurrence of blasts in the peripheral blood or inﬁltration of the
bone marrow (BM) by more than 5% blasts. Isolated EM relapse had to be
proven with biopsy.Table 2
Response and Outcomes to Salvage Treatment
Treatment N ¼ 93 (%)
Mild therapy 27 (29)
Single-agent chemotherapy (n ¼ 6):
(clofarabine, n ¼ 2; nelarabine, n ¼ 2; azacitidine,
n ¼ 1; hydrea, n ¼ 1)
Novel therapeutic agents/ trial medications (n ¼ 13)
Steroids/gentle chemotherapy (n ¼ 2)
TKIs (n ¼ 6)
Intensive chemotherapy 30 (32)
MTX /Ara C (n ¼ 4)
HyperCVAD/augmented
HyperCVAD [24] (n ¼ 20)
MOAD [25] ( n ¼ 4)
Others (n ¼ 2)
Radiotherapy or IT alone 6 (7)
DLI 11 (12)
þ Intensive chemotherapy (n ¼ 8)
þ Mild chemotherapy (n ¼ 3)
Second HSCT 19 (20)
þ Intensive chemotherapy (n ¼ 14)
þ Mild chemotherapy (n ¼ 5)
TRM indicates treatment-related mortality; MTX, methotrexate; Ara-C, cytarabin
adriamycin, and dexamethasone combined with methotrexate, cytarabine; MOADIST was deﬁned as being continued if not discontinued after relapse
until time of last follow-up or death or if patients died within 2 weeks of
stopping IST. Treatment regimens used for control of the leukemia after
relapse were deﬁned as intensive if a combination of cytotoxic agents was
used. Mild therapy was deﬁned as combinations of steroids and vincristine;CR Rates (%) Median OS (mo) Number, Cause of Death
41 4 TRM (n ¼ 1)
Disease relapse
(n ¼ 25)
27 4 TRM (n ¼ 2)
Disease relapse
(n ¼ 24)
Unknown (n ¼ 1)
83 3 TRM (n ¼ 1)
Disease relapse( n ¼ 4)
64 6.5 TRM (n ¼ 2)
Disease relapse (n ¼ 9)
84 10 TRM (n ¼ 5)
Disease relapse (n ¼ 8)
e; IT, intrathecal; HyperCVAD, fractionated cyclophosphamide, vincristine,
, methotrexate, vincristine, L-asparaginase, and dexamethasone.
Table 3
Univariate Analysis of Factors Inﬂuencing 6-Month OS after Relapse
Covariates N (123) Hazard Ratio 95% CI P
Age at HSCT, yr
30 55 Ref.
>30 68 .7 .5-1.1 .2
Sex
Female 39 Ref.
Male 84 1.7 1.01-2.8 .05
Lineage
B cell 95 Ref.
T cell 28 1 .6-1.7 .99
Cytogenetic
Ph 71 Ref.
Phþ 28 .7 .4-1.3 .2
Status at HSCT
CR1 28 Ref.
CR2/CR3 55 2.02 .9-4.3 .07
Active disease 40 3.1 1.4-6.7 .005
Preparative regimen
RIC 32 Ref.
HD 91 1.1 .6-1.8 .8
Allotype
Matched unrelated 45 Ref.
Matched related 65 .7 .5-1.2 .2
Cord blood 7 .8 .3-2.2 .6
Mismatched related 6 1.6 .6-4.2 .3
Time to relapse
>6 mo 42 Ref.
6 mo 81 2.05 1.2-3.4 .007
Site of relapse
Systemic 99 Ref.
Isolated EM 24 .8 .4-1.4 .4
RIC indicates reduced-intensity conditioning; HD, high-dose conditioning.
* Palliative group was excluded.
y Palliative group and nonassessable patients excluded.
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hydroxyurea; use of targeted therapies such as NOTCH inhibitors or tyrosine
kinase inhibitors (TKI); or use of immunomodulatory agents such as anti-
bodies or hypomethylating agents. Donor lymphocyte infusion (DLI) was
deﬁned as the infusion of unstimulated lymphocytes collected from the
original donor. Acute GVHD was clinically graded as 0 to IV based on stan-
dard criteria [12,13], and chronic GVHD was classiﬁed as none, limited, or
extensive as described previously [14].
Statistical Analysis
The primary outcome of interest was survival after relapse following
HSCT. Actuarial OS was estimated by the method of Kaplan-Meier. Survival
according to patients’ characteristics was compared using Cox’s propor-
tional hazards regression analysis. Comparison was limited to univariate
analysis because of sample size limitation and the heterogeneity of the
salvage therapy after relapse. Continuous variables were compared using
the Wilcoxon rank-sum test. Statistical signiﬁcance was deﬁned at the .05
level. Analysis was performed using STATA.11 (StataCorp LP, College Station,
TX).
RESULTS
Patient, Disease, and Relapse Characteristics
Between 1993 and 2011, 381 adults with ALL underwent
HSCT at M.D. Anderson Cancer Center, and 123 (32%)
subsequently relapsed. The patient characteristics are
summarized by the salvage treatment they received at time
of relapse in Table 1. For the whole group, the median age at
diagnosis was 31 years (range, 18 to 70 years, with 4 patients
older than 60 years). A signiﬁcant proportion of patients had
high-risk features, including 37% (n ¼ 46) with high-risk
cytogenetics (including 23% who were Phþ). In addition,
78% of patients (n ¼ 95) were that underwent tranplantation
beyond CR1, with 33% (n ¼ 40) that underwent tranplanta-
tion with active disease. Most patients received a myeloa-
blative conditioning regimen (74%, n ¼ 91).
Patients were that underwent tranplantation from
a sibling donor in 53% of cases (n ¼ 65), matched unrelated
donor in 37% (n ¼ 45), mismatched related donor in 5% (n ¼
6), and from a cord blood source in 6% (n ¼ 7). The source of
stem cells was peripheral blood for most patients (n ¼ 74).
The median time from transplantation to relapse was 4
months (range,1 to 38months). At the time of relapse, 80% of
patients (n¼ 99) had systemic relapse, whereas 20% (n¼ 24)
had isolated extramedullary relapse (Table 1).
Management of Relapse, Response, and Overall Survival
At the time of relapse, 23 patients received only
supportive care, whereas data on the treatment of 7 others
were limited because they were treated at other hospitals
after relapse. The remaining 93 patients received some form
of antileukemic therapy as described in Table 2. The choice of
initial salvage treatment was at the discretion of the
attending physician and patient and consisted of chemo-
therapy alone (mild, 22%; intensive, 24%), radiation therapy/
intrathecal therapy alone (5%), DLI chemotherapy (9%), and
HSCT  chemotherapy (15%). Of note, most patients who
received mild chemotherapeutic agents, including targeted
or immunomodulatory agents, were those that underwent
tranplantation after 2000. Among the Ph-positive patients
(n ¼ 28), 20 received TKIs (chemotherapy) as part of their
salvage therapy. Imatinib, a ﬁrst-generation TKI, was used in
relapses between 2001 and 2005 (n ¼ 9), whereas in most
relapses from 2006 onward, second-generation (dasatinib or
nilotinib) or third-generation (ponatinib) TKIs were used for
ﬁrst-line or subsequent salvage chemotherapy (n ¼ 11).
The decision to proceed to second transplantation was at
the discretion of the treating physician and involved patient.
Patients who received second transplantations were morelikely to be in CR (n ¼ 14/19) and had a relatively prolonged
duration of remission (>6 months) with their ﬁrst trans-
plantation (n ¼ 12/19) (Table 1). Donors for second HSCT
were changed in 47% of cases (n ¼ 9/19). Outcomes and
prognostic factors for second transplantations were reported
previously [15].
Overall, 38% of all patients achieved CR after their ﬁrst-
line salvage. With a median follow-up among surviving
patients of 11 months (range, 1 to 107 months), the median
OS rate in all patients was 4 months. The 1- and 2-year OS
rate for all patients was 17% (95% conﬁdence interval [CI], 13
to 29) and 1 % (95% CI, 6 to 20), respectively.
The median survival by treatment group was 10 months
in the second HSCT group; 6.5 months in the DLI group; 4
months in the chemotherapy-only group, with no difference
in survival whether intensive or mild chemotherapy was
administered; and 3 months in the radiation therapy or
intrathecal therapy group (Table 2). For patients who
received palliation only, the median survival was 1 month.
Disease status at time of ﬁrst transplantation and time to
relapse after ﬁrst transplantation were found to be signiﬁ-
cant predictors for worse survival in univariate analysis
(Table 3). Patient age, cytogenetic risk, and immunopheno-
type did not have a signiﬁcant impact on OS. Figure 1 shows
the OS rates among the patients who relapsed within
6 months after HSCT compared with those who relapsed
later.
Treatment and Outcomes of Patients with
Extramedullary Relapse
At the time of relapse, 85 patients had isolated BM
relapse, whereas 38 had relapse in EM sites, either isolated
(n ¼ 24) or with concurrent BM relapse (n ¼ 14) (Table 1).
Figure 1. Comparison of OS between patients who relapsed within 6 months
of HSCT and those who relapsed after 6 months.
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disease before HSCT. The central nervous system (CNS) was
the most common site of EM relapse (n ¼ 25), followed by
mediastinal masses/lymph node involvement (n ¼ 8) and
testicular involvement (n¼ 2). Five patients had more than 1
site of EM relapse. Among the 25 patients with CNS relapse,
52% (n ¼ 13) had CNS disease before their transplantation.
The median time from transplantation to relapse was similar
among the patients with isolated relapse (7 months; range, 1
to 28) compared with patients with systemic relapse (4
months; range, 1 to 38), P ¼ .3.
Among the 24 patients with isolated EM relapse, 20
received treatment as described: radiation  intrathecal
therapy (n ¼ 6), DLI (n ¼ 1), chemotherapy  radiotherapy/
intrathecal (n ¼ 11), and chemotherapy followed by HSCT
(n ¼ 2). CR to salvage therapy was noted in 70% of patients
(n ¼ 14), but 50% relapsed again and ultimately died from
disease-related complications. Among the 7 patients who
achieved a durable CR, only 3 patients with isolated CNS
relapse remain alive and disease free, all having received
systemic therapy (1 patient after chemotherapy and radio-
therapy followed by a second transplantation and 2 patients
after chemotherapy and radiotherapy only). Three patients
-died of treatment-related complications while in remission,
and 1 was lost to follow-up. There was no signiﬁcant differ-
ence in survival among patients with isolated EM relapse
compared with those with combined BM/EM relapse or
those with isolated BM relapse: 6-month OS, 44% (95% CI, 24
to 63), 29% (95% CI, 9 to 52), and 34% (95% CI, 24 to 44),
respectively.Outcomes Associated with IST Withdrawal
Sixty-six patients had IST withdrawal at the time of
relapse. Of these patients, 9 did not receive any further
antileukemic therapy, did not show any response to IST
withdrawal, and died of disease progression. Fifty-four
patients received salvage therapy in addition to IST with-
drawal, among which 44% (n ¼ 24) attained a CR with ﬁrst-
line salvage. However, only 2 patients remain alive and
disease-free (1 patient after a second transplantation and 1
patient still receiving intensive chemotherapy), whereas 45
died of persistent disease and 7 died fromvarious treatment-
related complications. Three patients were lost to follow-up.
Twenty-six percent of patients who had IST withdrawal attime of relapse (n ¼ 17) developed GVHD, with 17% (n ¼ 11)
occurring within 3 months of stopping IST and 9% (n ¼ 6)
developing after subsequent DLI. The incidence of acute
GVHD grades II to IV was 23% (n¼ 15) and grades III to IV was
3% (n ¼ 2). Two patients developed chronic GVHD.
Assessment of the EBMT Scoring System
A recent report from the EBMT analyzing the prognostic
factors that affected postrelapse OS indicated that by using
a combination of 3 prognostic factors (disease status at the
time of transplantation, interval from transplantation to
relapse, and number of peripheral blasts at the time of
relapse), 3 different prognostic groups for survival could be
identiﬁed9. When this EBMT prognostic score was applied to
the patients in our study who underwent tranplantation in
remission, we found a similar trend: the median survival
rates in patients with 0, 1, 2, and 3 risk factors were 10
months, 6 months, 3 months, and 2 months, respectively.
DISCUSSION
We present data on a large cohort of adult ALL patients
who relapsed after HSCT from a single center and were
treated over an 18-year period. The relatively large sample
size and long follow-up allowed us to investigate key issues
in this patient population that has not beenwell studied. One
important observation is the incidence, nature, and prog-
nosis of isolated EM relapses after HSCT. Among the 381
transplantations performed for ALL during this study period,
we report an EM relapse rate of 10%, with an isolated EM rate
of 6%, which are very similar to that reported in the literature
[16-18]. However, unlike other studies in the literature on EM
relapse after allogeneic transplantation [17], we found no
differences in survival outcomes after isolated EM relapse
compared with systemic relapse (Table 3).
Importantly, our study was limited to only ALL. The
inclusion of patients with other hematological malignancies,
in particular acute myelogenous leukemia (AML), may
account for the conﬂicting results. A recent study by a Min-
nesota group looking solely at patients with AML and EM
relapse after HSCT demonstrated a signiﬁcantly better
probability of 6-month survival in the patients with isolated
EM relapse (69%) compared with those with combined BM
and EM relapse (8%) or those with BM relapse alone (27%)
(P< .01) [19]. In contrast, we report survival rates of 44% (95%
CI, 24 to 63), 29% (95% CI, 9 to 52), and 34% (95% CI, 24 to 44)
in the isolated EM, combined BM/EM, and isolated BM
relapse groups, respectively (P ¼ .8). The contrast in the
ﬁndings between the studies suggests that the prognosis of
isolated EM relapse after HSCT depends on the disease
subtype and may be poorer in patients with ALL compared
with AML. Differences in disease biology, including the
propensity of ALL to inﬁltrate immunological sanctuary sites
such as the CNS and testis, as well as variation in treatment,
including the up front use of CNS prophylaxis in ALL, all likely
contribute to the different outcomes for ALL and AML. The
treatment options for isolated EM relapse have typically
included radiotherapy and/or intrathecal therapy; the role of
systemic therapy in this setting remains less clear. In our
study, all 3 long-term survivors with isolated EM disease
received some form of systemic therapy.
We also attempted to draw some conclusions regarding
the optimal management of IST at the time of relapse.
Discontinuation of IST with the aim of inducing a graft-ver-
sus-leukemia effect has been a common practice in
patients who relapse after allogeneic transplantation.
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inducing long-term remission with IST withdrawal alone
[20,21], larger studies looking at this have suggestedminimal
efﬁcacy for this approach, especially in patients with acute
leukemia [22]. One limitation of trying to evaluate the impact
of IST withdrawal in a retrospective study is the fact that IST
withdrawal is often used in combination with antileukemia
therapy rather than as a sole modality of treatment. In our
study, 11 of 17 patients who developed GVHD after IST
withdrawal developed remission to their ﬁrst-line salvage
therapy. The close proximity between the timing of IST
withdrawal, the development of GVHD, and the use of anti-
leukemia therapy in these patients, however, makes it difﬁ-
cult to ascertain the speciﬁc contribution of each event to
graft-versus-leukemia and leukemia response. Neverthe-
less, in our study, the ﬁndings that none of the 9 patients
who had IST withdrawal alone attained remission and the
fact that only 2 patients achieved long-term remission
among the 66 patients with IST withdrawal (both of whom
had received other antileukemic therapy) suggest a likely
minimal efﬁcacy of such a strategy in this patient population.
Furthermore, there is the concern of inducing GVHD after IST
withdrawal, particularly in patients who relapse early after
HSCT or in patients who receive further chemotherapy that
may induce a cytokine-abundant environment. We noted an
acute grades II to IV GVHD rate of 17% after IST discontinu-
ation. The subsequent salvage treatment, which commonly
includes steroids in ALL, also likely impacts the GVHD rate.
Thus, the complexity of the patient at time of transplantation
makes it difﬁcult for us to make deﬁnitive conclusions.
However, given the potential life-threatening toxicities
associated with GVHD and the minimal impact of IST with-
drawal on disease control, it is reasonable to continue low-
dose immune suppression at time of relapse.
The inclusion in our study of patients over an 18-year
period provided a reﬂection of the paradigm shift in treat-
ment strategies over time in this ﬁeld. This included the
increased use of noncytotoxic therapeutic agents, such as
monoclonal antibodies and TKI therapies, during the last
decade. The retrospective nature of our study, however,
precluded the ability to determine the optimal salvage
regimen or agents. The best survival was seen in patients
who received a second transplantation (Table 2), although
these ﬁndings are likely biased by the fact that these patients
had good response to salvage therapy and needed to have
survived long enough to receive their second trans-
plantation. More importantly, although a second trans-
plantation is likely the only curative options for these
patients, the generally high treatment-related mortality and
poor outcomes of second transplantations for relapsed ALL
[15] make it difﬁcult to justify this procedure currently
except for possibly a small selected subgroup of patients or
in the context of clinical trials with novel therapeutic
interventions. Whether the advent of promising novel
agents including monoclonal antibody therapies will lead to
an improvement in outcomes remains as yet unclear and
will depend on the results of prospective studies in this ﬁeld.
In our study, the median OS after relapse was 4 months
and the 2-year OS rate was 10%, which are very similar to the
registry data reported by the EBMT group (median OS after
relapse of 5.5 months and 2-year OS rate of 16%  2%)9. In
addition, in our univariate analysis for survival, our study
ﬁndings were consistent with that of EBMT registry data
with respect to the prognostic value of relapse-related
characteristics, including active disease at the time of ﬁrstHSCT (hazard ratio ¼ 1.8, P ¼ .01) and short duration of
relapse (6months) from ﬁrst HSCT (hazard ratio ¼ 2.05, P ¼
.007) as well as the lack of prognostic signiﬁcance for
disease-related characteristics, such as immunophenotype
and cytogenetic classiﬁcation at diagnosis (Table 3). Finally,
we were able to corroborate the EBMT scoring system to
prognosticate outcome after transplantation relapse. We
noted a signiﬁcant difference in median OS for the good-
prognosis group (score 0/1) compared with the poor-
prognosis group (score 2/3) (median OS of 7 months versus
3 months, P ¼ .009). However, given the constraints of
a retrospective analysis, we cannot exclude the possibility
that patients with shorter time to relapse andmore extensive
prior therapy to transplantation might have been more likely
offered a palliative approach, hence biasing our ﬁndings.
In conclusion, survival of patients with ALL who relapse
after transplantation is extremely poor, with no difference in
outcome between patients with isolated EM versus systemic
relapse, suggesting that all relapse should be treated
systemically. Furthermore, abrupt discontinuation of
immune suppression at time of relapse does not result in
clinical beneﬁt and may result in more GVHD; thus,
continued low-dose immune suppression may be the
optimal approach. Finally, reinduction and second trans-
plantation in a highly selected patient group offers the best
chance for prolonged survival. Ultimately, these data
emphasize the need for continued research in preventing,
rather than treating, relapse. Increased use of minimal
residual disease monitoring, preemptive immunothera-
peutic interventions, and posttransplantation maintenance
strategies should be considered [23].
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